What Is Calcitonin? Benefits, Research & Safety
A thyroid hormone involved in calcium regulation, used therapeutically for osteoporosis, Paget's disease, and hypercalcemia.
UK summary: UK prescription-only medicine (Miacalcic). Long-term osteoporosis use was restricted in 2013 following EMA review of cancer-risk signals; short-term use for hypercalcaemia and Paget's disease remains appropriate.
Quick Facts
Overview
Calcitonin — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
UK prescription-only medicine (Miacalcic). Long-term osteoporosis use was restricted in 2013 following EMA review of cancer-risk signals; short-term use for hypercalcaemia and Paget's disease remains appropriate.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Available for specific indications; use restricted to short-term treatment.
- EU: Use restricted due to cancer risk concerns; limited indications.
- Notes: Calcitonin use has been restricted in many jurisdictions following EMA recommendations in 2013. Long-term use for osteoporosis is no longer recommended. Short-term use for hypercalcemia and Paget's disease remains appropriate.
05Approved medical uses
- Hypercalcaemia (acute / cancer-related — Miacalcic IV).
- Paget's disease of bone (short-term).
- Acute vertebral fracture pain (nasal calcitonin — limited modern use).
06Unapproved / promotional claims
- Calcitonin as first-line long-term osteoporosis treatment.
- Daily calcitonin nasal spray for healthy adults.
07Common internet claims
- Some online sources still promote calcitonin for osteoporosis prevention despite restricted indication.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Best long-term option for osteoporosis” | B | Yes | High | Calcitonin is no longer recommended for long-term osteoporosis treatment due to cancer-risk signals; bisphosphonates / denosumab / teriparatide are typical first-line. |
09Safety uncertainty score
Safety profile partly characterised; some signals from observational or preclinical data.
10Known adverse signals
- EMA / MHRA cancer-risk signal restricted long-term osteoporosis use (2013).
- Nasal irritation, flushing.
- Antibody formation with chronic use.
11Drug-interaction uncertainty
Some interaction data published; check with a prescriber for your specific medicines.
12Anti-doping status
13UK legal position
Available for specific indications; use restricted to short-term treatment.
14EU legal position
Use restricted due to cancer risk concerns; limited indications.
15What this page cannot tell you
- Whether off-label long-term use carries the same cancer signal as restricted indication.
16Last reviewed
17Citation quality score
18Research gaps
- Superseded by bisphosphonates / denosumab / teriparatide for routine osteoporosis.
19Safer alternatives / established care pathways
- NICE TA161 / TA204 osteoporosis pathway: lifestyle + calcium / vitamin D + bisphosphonate first-line.
- Specialist referral for severe / refractory cases.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- What is the appropriate UK osteoporosis treatment for my situation?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Rapid reduction of hypercalcemia
- 2Reduction of bone turnover in Paget's disease
- 3Pain relief in vertebral fractures and bone disease
- 4Modest reduction in vertebral fracture risk (osteoporosis)
- 5Important tumor marker for medullary thyroid cancer
Claim vs Evidence
How popular claims about Calcitonin stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Best long-term option for osteoporosis” | B | Yes | High | Calcitonin is no longer recommended for long-term osteoporosis treatment due to cancer-risk signals; bisphosphonates / denosumab / teriparatide are typical first-line. |
Theoretical Dosing & Protocols
| Theoretical Dosage | Varies by indication; 200 IU nasal daily for osteoporosis; 4-8 IU/kg injection for hypercalcemia |
| Frequency | Daily (nasal) or as needed (injection) |
| Duration | Limited duration recommended due to cancer concerns |
| Notes | Calcitonin use has declined due to availability of better alternatives and cancer risk concerns. It remains useful for specific situations like acute hypercalcemia and Paget's disease. Use should be time-limited. |
Administration Routes
Routes studied in research settings (educational only):
- Nasal spray (osteoporosis, most convenient)
- Subcutaneous or intramuscular injection
- Intravenous (hypercalcemia emergencies)
| Half-Life | Stability |
|---|---|
| Approximately 10-15 minutes (short) | Commercial preparations stable per manufacturer specifications |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Nasal irritation and rhinitis (nasal spray)
- Nausea
- Flushing
- Injection site reactions
- Allergic reactions (especially salmon-derived)
Rare Risks & Concerns
- Increased cancer risk with long-term use
- Serious allergic/anaphylactic reactions
- Hypocalcemia (excessive effect)
Contraindications
- Known hypersensitivity to calcitonin
- Hypocalcemia
- Long-term use discouraged
UK & EU Regulatory Context
🇬🇧 United Kingdom
Available for specific indications; use restricted to short-term treatment.
🇪🇺 European Union
Use restricted due to cancer risk concerns; limited indications.
Clinical Studies Summary
Neurophysiological Effects of Dry Needling: A Systematic Review and Meta-analysis.
The application of dry needling can induce significant changes in pain-related biomarker levels in animal and human studies, providing insights into its underlying mechanisms of action and potential clinical effects.
Safety and efficacy of calcitonin gene-related peptide antagonists for cluster headache: a systematic review and meta-analysis.
Calcitonin gene-related peptide antagonists provide preventive benefit with acceptable safety in cluster headache. These findings should be interpreted as supportive but less definitive. Larger, long-term, placebo-controlled randomized trials are needed to confirm efficacy and guide clinical use.
Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis.
Tirzepatide use in RCTs over 26 to 72 weeks did not increase overall or specific cancer risk.
Comparative Effectiveness of Pharmacologic Treatments for the Prevention of Episodic Migraine Headache: A Systematic Review and Network Meta-analysis for the American College of Physicians.
No high-certainty evidence favored one pharmacologic treatment for prevention of episodic migraine over another. Evidence was mostly insufficient or of low certainty.
Network meta-analysis comparing efficacy of different strategies on medication-overuse headache.
Combination therapies, including anti-CGRP(R) therapies and nerve blocks, appear to be the most effective strategies for MOH management, highlighting their potential as initial treatment options. While headache prevention strategies demonstrated similar efficacy, abrupt withdrawal alone was insufficient.
PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis.
R. declares that he has received consulting fees or has been on paid advisory boards for IBSA-Genevrier, Viatris, Radius Health, Rejuvenate Biomed, Celltrion, Promedius, and Theramex; received lecture fees when speaking at the invitation of the sponsor for IBSA-Genevrier, Theramex, and Viatris; and received grant support from IBSA-Genevrier, Viatris, Radius Health, and TRB, all through institutions and outside the su…
Registered Trials & Regulatory Status
22 of 29 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.
Calcitonin Gene-related Peptide Antibody in Acute Mountain Sickness
Status: Not Yet Recruiting · 30 participants · Insel Gruppe AG, University Hospital Bern
Conditions: Acute Mountain Sickness
Adding Calcitonin to Bupivacaine in Transversalis Fascia Plane Block for Cesarean Section
Status: Recruiting · 70 participants · Tanta University
Conditions: Transversalis Fascia Plane Block
Paravertebral Calcitonin in Thoracotomy
Status: Completed · 92 participants · Tanta University
Conditions: Calcitonin, Paravertebral, Thoracotomy
Evaluation of the Levels of Calcitonin Gene-related Peptide and Substance P
Status: Recruiting · 51 participants · Melike Cengiz
Conditions: Meningitis, Diagnosis, Prognosis
Ultrasound Guided Block of Stellate Ganglion Versus Greater Occipital Nerve in Resistant Migraine and Correlation to Calcitonin Gene Related Peptide
Status: Recruiting · 40 participants · Ain Shams University
Conditions: Migraine
Evaluate the Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Antagonists in Patients With Dry Eye Disease and Asthenopia
Status: Completed · 103 participants · Nvision Laser Eye Centers
Conditions: Dry Eye, Asthenopia
Stimulation-evoked Calcitonin Gene-Related Peptide (CGRP) as Biomarker of Migraine
Status: Unknown · 20 participants · University Medicine Greifswald
Conditions: Migraine
The Lacosamide's Effect on Calcitonin Gene-related Peptide in Migraine Patients
Status: Completed · 200 participants · Kafrelsheikh University
Conditions: Effect of Drug, Migraine Disorders
Calcitonin Level and New-onset of Post-Operative Atrial Fibrillation
Status: Unknown · 200 participants · Tongji Hospital
Conditions: Calcitonin Secretion Disorder, Post-operative Atrial Fibrillation
Efficacy of Coadministration of Calcitonin and Hyperbaric Bupivacaine in Spinal Anesthesia in Tramadol-abuse Patients
Status: Completed · 90 participants · Ain Shams University
Conditions: Analgesia
The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients
Status: Unknown · 72 participants · Danish Headache Center
Conditions: Migraine, Migraine Without Aura, Migraine With Aura
The Use of Intranasal Calcitonin to Improve Pain and Activity in Elderly Pelvic Ring Injuries
Status: Completed · 21 participants · University of Missouri-Columbia
Conditions: Pelvic Ring Fractures
Adverse event reports (FDA FAERS)
- drug ineffective448
- nausea205
- off label use193
- fatigue178
- death150
- hypercalcaemia150
- fall144
- diarrhoea136
- pain133
- vomiting128
FDA FAERS spontaneous reports. A report is not proof the substance caused the event, and an absence of reports is not evidence of safety.
Source: ClinicalTrials.gov and openFDA. Updated automatically.
Looking for Calcitonin?
Source research-grade Calcitonin from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Calcitonin
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- What is the appropriate UK osteoporosis treatment for my situation?
UK regulatory & safety context
Related Peptides
ACTH
A pituitary hormone that stimulates cortisol production, used diagnostically and therapeutically for various conditions including infantile spasms.
Learn moreAmylin
A pancreatic hormone co-secreted with insulin that regulates glucose and appetite, the basis for the diabetes drug pramlintide.
Learn morePTH 1-34
The biologically active fragment of parathyroid hormone approved for osteoporosis treatment, representing the first anabolic bone therapy.
Learn more